Sporadic breast cancers only rarely contain BRCA2 or BRCA1 mutations, despite the presence of such mutations in inherited breast and ovarian cancers. The identification of a new binding partner for BRCA-2 sheds light on this incongruity.
This is a preview of subscription content, log in via an institution to check access.
Renee Lucas
References
Mueller, C.R. & Roskelley, C.D. Breast Cancer Res. 5, 45–52 (2003).
Hughes-Davies, L. et al. Cell 115, 523–535 (2003).
Maurer-Stroh, S. et al. Trends Biochem. Sci. 28, 69–74 (2003).
Nielsen, P.R. et al. Nature 416, 103–107 (2002).
Jacobs, S.A. & Khorasanizadeh, S. Science 295, 2080–2083 (2002).
Lachner, M., O'Carroll, D., Rea, S., Mechtler, K. & Jenuwein, T. Nature 410, 116–120 (2001).
Akhtar, A.D., Zink, D. & Becker, P. Nature 407, 405–409 (2000).
Volpe, T. et al. Science 297, 1833–1837 (2002).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Livingston, D. EMSY, a BRCA-2 partner in crime. Nat Med 10, 127–128 (2004). https://doi.org/10.1038/nm0204-127
Issue Date:
DOI: https://doi.org/10.1038/nm0204-127
- Springer Nature America, Inc.
This article is cited by
-
EMSY stabilization in KEAP1-mutant lung cancer disrupts genome stability and type I interferon signaling
Cell Death & Differentiation (2023)
-
Genetics of eosinophilic esophagitis
Mucosal Immunology (2017)
-
Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers
Breast Cancer Research and Treatment (2010)
-
Absence of allelic imbalance involving EMSY, CAPN5, and PAK1 genes in papillary thyroid carcinoma
Journal of Endocrinological Investigation (2008)
-
Common variation in EMSYand risk of breast and ovarian cancer: a case-control study using HapMap tagging SNPs
BMC Cancer (2005)